AtCor signs $800K contract expansion
AtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
Following its recent announcement of a 1H13 profit, AtCor Medical has now added a further $800,000 to its expected revenues following the signing of a contract expansion to an existing customer.
AtCor will supply SphygmoCor to a major pharmaceutical company to support clinical trials in North and South America, Europe and Asia.
SphygmoCor is the company’s device for measuring central aortic blood pressures and arterial stiffness non-invasively.
“We are delighted to have secured this expansion contract,” said AtCor Medical CEO Duncan Ross.
“The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs.”
AtCor (ASX:ACG) was up 1% at 10c in light trading as of around 11 am Monday morning.
Stevia leaf extract has potential as an anticancer treatment
When fermented with bacteria isolated from banana leaves, stevia extract kills off pancreatic...
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
